Status:
UNKNOWN
BEOVU Versus Eylea in the Treatment of Age-related Macular Neovascular Degeneration
Lead Sponsor:
Benha University
Conditions:
Macula Lutea Degeneration
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Age-Related macular neovascularization degeneration occur is a vision threatening condition. The investigators compare the efficacy of BEOVU and Eylea intravitreal treatment in the management.
Detailed Description
Baseline ,and postoperative 1 ,6 and 12 months full ophthalmic examination was done. Procedure included randomized intravitreal injection of Brolucizumab (BEOVU®, Genentech, South Francisco, CA) and o...
Eligibility Criteria
Inclusion
- • Age-Related macular neovascularization degeneration
Exclusion
- other causes of macular neovascularization degeneration
- other macular diseases
Key Trial Info
Start Date :
August 5 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2022
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04882956
Start Date
August 5 2020
End Date
March 1 2022
Last Update
May 12 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
INMC
Abu Dhabi, United Arab Emirates, 46266